Axinn Successfully Obtains Dismissal of Certain Patent Claims asserted against Zydus Pharmaceuticals in Boehringer Ingelheim Pharmaceuticals, Inc. v. HEC Pharma Co., Ltd.
December 19, 2016
A team of Axinn attorneys successfully obtained a dismissal of certain patent claims brought by Boehringer Ingelheim Pharmaceuticals against several defendants, including Axinn client Zydus Pharmaceuticals. On December 7, the United States District Court for the District of New Jersey granted the Defendants’ joint motion to dismiss the claims of patent infringement relating to U.S. Patent No. 8,853,156, which is alleged by Boehringer to cover its antidiabetic drug Tradjenta (linagliptin).
At issue in the matter was whether claims that recite a method of treating metabolic diseases by administering DPP-IV inhibitors to certain patients are patent eligible under 35 U.S.C. § 101. The Defendants challenged the asserted certain of the ‘156 patent on grounds that they recite a natural law and are therefore patent ineligible. The plaintiffs argued that the claims were patent eligible because they recite treating specific populations using non-natural compounds and alter the state of the body in a new and useful way.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
LCA 2026 Renaissance Symposium XX
Speaking Engagement
Antitrust
Concurrences New Frontiers of Antitrust Conference 2026
Sponsorship
Antitrust
Stakeholders 26th Annual CYOC Conference
Event
Antitrust
Hot Topics in Health Care Antitrust
Podcast
Antitrust
Jimmy Attridge Repeats Recognition on Washingtonian Magazine’s 2026 Top Lawyers List
Awards & Recognitions
Antitrust
AIC General Counsel Day 2026
Speaking Engagement
Antitrust
ALFDP 20th Anniversary Annual Conference
Event
Antitrust
Antitrust After the Midterms: Planning for a Blue Wave of Congressional Investigations
Axinn Viewpoints
Antitrust
GCR Live: Women in Antitrust 2026
Sponsorship
Antitrust
GICLI Annual Meeting 2026
Sponsorship
Antitrust